Cargando…
DUSP22-rearranged ALK-negative anaplastic large cell lymphoma is a pathogenetically distinct disease but can have variable clinical outcome
Autores principales: | Savage, Kerry J., Slack, Graham W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230405/ https://www.ncbi.nlm.nih.gov/pubmed/36453106 http://dx.doi.org/10.3324/haematol.2022.282025 |
Ejemplares similares
-
DUSP22 rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma
por: Qiu, Lianqun, et al.
Publicado: (2022) -
Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement
por: Magaki, Shino, et al.
Publicado: (2021) -
ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study
por: Sibon, David, et al.
Publicado: (2022) -
Primary cutaneous anaplastic large‐cell lymphoma with
DUSP22‐IRF4
rearrangement following insect bites
por: Zhang, Yaping, et al.
Publicado: (2021) -
Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
por: Subbiah, V., et al.
Publicado: (2021)